DE69821228D1 - SELECTIVE MMP INHIBITORS WITH REDUCED SIDE EFFECTS - Google Patents

SELECTIVE MMP INHIBITORS WITH REDUCED SIDE EFFECTS

Info

Publication number
DE69821228D1
DE69821228D1 DE69821228T DE69821228T DE69821228D1 DE 69821228 D1 DE69821228 D1 DE 69821228D1 DE 69821228 T DE69821228 T DE 69821228T DE 69821228 T DE69821228 T DE 69821228T DE 69821228 D1 DE69821228 D1 DE 69821228D1
Authority
DE
Germany
Prior art keywords
reduced side
side effects
mmp inhibitors
mmp
selective mmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69821228T
Other languages
German (de)
Other versions
DE69821228T2 (en
Inventor
John Bird
Gary Montana
Elizabeth Wills
Douglas Baxter
Alan Owen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darwin Discovery Ltd
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704350.9A external-priority patent/GB9704350D0/en
Priority claimed from GBGB9802622.2A external-priority patent/GB9802622D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of DE69821228D1 publication Critical patent/DE69821228D1/en
Application granted granted Critical
Publication of DE69821228T2 publication Critical patent/DE69821228T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The subject invention pertains to matrix metalloproteinase (MMP) inhibitors that exhibit an IC50 of below 10<-4>M against MMP and have substantially no activity against non-MMP metalloproteinase-related events. The MMP inhibitors of the invention have reduced side-effects, especially with respect to joint pain.
DE69821228T 1997-03-03 1998-03-03 SELECTIVE MMP INHIBITORS WITH REDUCED SIDE EFFECTS Expired - Fee Related DE69821228T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9704350.9A GB9704350D0 (en) 1997-03-03 1997-03-03 Compounds and their therapeutic use
GBGB9802622.2A GB9802622D0 (en) 1998-02-06 1998-02-06 Compounds and their therapeutic use
PCT/GB1998/000659 WO1998039024A1 (en) 1997-03-03 1998-03-03 Selective mmp inhibitors having reduced side-effects

Publications (2)

Publication Number Publication Date
DE69821228D1 true DE69821228D1 (en) 2004-02-26
DE69821228T2 DE69821228T2 (en) 2004-10-21

Family

ID=26311105

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69821228T Expired - Fee Related DE69821228T2 (en) 1997-03-03 1998-03-03 SELECTIVE MMP INHIBITORS WITH REDUCED SIDE EFFECTS

Country Status (9)

Country Link
US (1) US6818622B2 (en)
EP (1) EP0981366B1 (en)
JP (1) JP2001513813A (en)
AT (1) ATE258063T1 (en)
AU (1) AU741903C (en)
CA (1) CA2280134A1 (en)
DE (1) DE69821228T2 (en)
ES (1) ES2212270T3 (en)
WO (1) WO1998039024A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002528461A (en) * 1998-10-23 2002-09-03 ダーウィン・ディスカバリー・リミテッド Monomorphic forms of known peptide metalloproteinase inhibitors
WO2001026671A1 (en) * 1999-10-12 2001-04-19 Smithkline Beecham Corporation Methods of treatment using dual matrix-metalloproteinase-2 and matrix metalloproteinase-9 inhibitors
CN101456860B (en) * 2007-12-10 2011-02-16 中国科学院上海药物研究所 Process for preparing 4-[9-(6-aminopurine)]-2(S)-hydroxybutyrate methyl ester
EP2234608A2 (en) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
ES2134939T3 (en) * 1993-04-27 1999-10-16 Celltech Therapeutics Ltd PEPTIDYL DERIVATIVES AS METALOPROTEIN INHIBITORS.
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
DK0784629T3 (en) * 1994-10-05 1999-10-25 Darwin Discovery Ltd Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
EP0824543A1 (en) * 1995-05-10 1998-02-25 Chiroscience Limited Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use
HUP0003760A3 (en) * 1995-10-05 2001-05-28 Darwin Discovery Ltd Cambridge Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation, process for production thereof and their use
GB9523066D0 (en) * 1995-11-10 1996-01-10 Chiroscience Ltd Compounds and their therapeutic use

Also Published As

Publication number Publication date
AU741903C (en) 2002-09-05
JP2001513813A (en) 2001-09-04
EP0981366A1 (en) 2000-03-01
US6818622B2 (en) 2004-11-16
US20020035065A1 (en) 2002-03-21
CA2280134A1 (en) 1998-09-11
AU6630698A (en) 1998-09-22
WO1998039024A1 (en) 1998-09-11
EP0981366B1 (en) 2004-01-21
ES2212270T3 (en) 2004-07-16
AU741903B2 (en) 2001-12-13
DE69821228T2 (en) 2004-10-21
ATE258063T1 (en) 2004-02-15

Similar Documents

Publication Publication Date Title
MA26812A1 (en) PYRIMIDINE-2,4,6-TRIONES INHIBITORS OF METALLOPROTEINASES
MY129409A (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
TR28718A (en) Dynamically tracked type of diaper.
DE69925133D1 (en) PYRROLOBENZODIAZEPINE
DE69621021T2 (en) INHIBITORS OF THE PLATE AGGREGATION
ATE282600T1 (en) NITRIC ACID SALTS OF ANTIHYPERTENSIVE DRUGS
EP0935963A3 (en) The use of MMP-13 selective inhibitors for the treatment of osteoarthritis and other matrix metalloproteinase-mediated disorders
YU53899A (en) Use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing cardiovascular disorders
ATE266000T1 (en) HYDROXAMIC ACID AND CARBOXIC ACID DERIVATIVES WITH MMP AND TNF INHIBITING EFFECTS
DE69115280T2 (en) INDOLDER DERIVATIVES THAT INHIBIT LEUKOTRIA BIOSYNTHESIS.
AR015379A1 (en) ASCORBIL-FOSFORIL-CHOLESTEROL
DE69716934T2 (en) 1,3-DIHETEROCYCLIC METALOPROTEASE INHIBITORS
NO20002479L (en) Combination of angiotensin converting enzyme inhibitor and a diuretic for the treatment of microcirculatory disorders
DE4494827D2 (en) Active silencer
BR9809848A (en) Composition
IT1302243B1 (en) SUMMARY OF 1,1,1,3,3-PENTAFLUOROPROPANO.
ZA978307B (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase.
TR199900505T2 (en)
ATE228760T1 (en) THROMBIN INHIBITORS
ID24677A (en) COMBINATION OF FUNICIDAL ACTIVE COMPOUNDS
DE69800357D1 (en) SOLID, NON-FLOWABLE FORMULATION OF SODIUM VALPROAT
DE69821228T2 (en) SELECTIVE MMP INHIBITORS WITH REDUCED SIDE EFFECTS
ATE320422T1 (en) METALLOPROTEINASE INHIBITORS
ES2166816T3 (en) PIRIDIL-IMIDAZOLIC DERIVATIVES AND PROCEDURES FOR THEIR PREPARATION.
ATE28188T1 (en) ANTICONVULSE AGENTS.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee